Semaglutide Shot: Injection Format, Titration, Options

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where GLP-1 science gets unpacked one honest question at a time. Browse the full Peptides & GLP-1 library to see how the topics connect.

When people search "semaglutide shot," they are usually asking a format question: is there an injection version, is there a pill version, and what changes between them in practice as of April 2026? This page reports the format reality plainly, explains the bioavailability trade-offs behind it, and covers how PlexusDx offers each format through its Weight Management Protocols.

Framing the shot as one of two doors into the same pathway keeps the comparison honest. The injection is not a different drug from the oral tablet in mechanism; it is a different way of delivering a shared effect. That distinction shapes almost every practical question that follows about timing, tolerance, and cost.

What the semaglutide shot refers to

The shot is the injectable route for a GLP-1 receptor agonist, and it is one of two delivery formats the class uses. Semaglutide is available in the FDA-approved market in the format indicated on the relevant product label, so the current authorized formats are best confirmed in the prescribing information or with a healthcare provider. The takeaway is that the injection and the oral tablet are two doors into the same GLP-1 mechanism.

Injection versus oral: the bioavailability trade-off

Injectable GLP-1 receptor agonists deliver predictable bioavailability and are typically dosed once weekly, or once daily in the case of liraglutide. Oral GLP-1 receptor agonists face a harder problem, because a peptide has to survive gastric digestion; Rybelsus addresses this with an absorption enhancer known as SNAC and requires strict fasting administration. Real-world adherence hinges on patient preference, injection tolerance, timing requirements, and lifestyle. Head-to-head weight-management efficacy data between oral and injectable semaglutide is limited, and oral semaglutide is labeled for type 2 diabetes rather than weight management.

How label titration schedules are structured

Injectable semaglutide is titrated per its product label from 0.25 mg weekly toward higher doses, with Ozempic labeled up to 2 mg and Wegovy up to 2.4 mg. Injectable tirzepatide is titrated from 2.5 mg weekly toward higher doses, with Mounjaro and Zepbound labeled up to 15 mg. Rybelsus, the oral semaglutide, starts at 3 mg daily and titrates to 7 or 14 mg daily. None of this substitutes for a prescriber's direction; it simply shows why titration is a defining feature of the shot rather than an afterthought.

Cost and coverage differ by format

Oral and injection formats are priced separately, follow different insurance coverage rules, and may have different eligibility for manufacturer savings programs. That means the format decision is partly clinical and partly practical, and the two answers do not always point the same way. PlexusDx Weight Management Protocols publish per-protocol pricing on the relevant product pages, so the numbers attach to the specific format rather than to a single blended figure.

Genetics upstream of the format choice

The format is a delivery decision; the biology underneath it is inherited. Variants in FTO, GLP1R, and MC4R shape baseline appetite and energy-balance tendencies regardless of whether the compound arrives by needle or by mouth. They do not predict how a shot will perform for you. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, giving that upstream context before a format is chosen. PlexusDx offers both routes, including a Semaglutide Injection protocol, with genetics framing the decision rather than following it.

In the end, choosing between the shot and an oral option is part clinical and part logistical, and the two answers do not always agree. Weighing predictable bioavailability against convenience and daily timing is a conversation for a provider who can align the format with your indication and routine.

Frequently Asked Questions

Is there an oral version as well as the shot?

Yes. As of April 2026, Rybelsus is the only FDA-approved oral GLP-1 receptor agonist, and it is labeled for type 2 diabetes rather than weight management. There is no FDA-approved oral tirzepatide. PlexusDx offers separate oral semaglutide and tirzepatide protocols within its Weight Management Protocols.

How does the shot compare with the oral form?

Injection delivers predictable bioavailability with once-weekly dosing, while oral semaglutide uses an absorption enhancer and requires strict fasting administration per its label. Head-to-head weight-management efficacy data between the two is limited, and oral semaglutide is approved for type 2 diabetes, not chronic weight management.

How is the injection dose adjusted over time?

Injectable semaglutide is titrated per its label from a low starting dose upward, and injectable tirzepatide follows its own titration schedule. The purpose is to ease tolerability as the body adjusts. Your prescriber sets the actual schedule based on the FDA-approved indication and your individual response.

Does the genetic test tell me which format to pick?

No. The Precision Peptide Genetic Test does not predict response to any compound or format. It reads pathway-level variants such as FTO, GLP1R, and MC4R that shape baseline biology, providing upstream context that applies whether the compound is delivered by injection or by mouth.

Keep exploring the PlexusDx Education Hub for more evidence-first GLP-1 guidance. Return to the education hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.